vs
バイオジェン（BIIB）とFidelity National Information Services（FIS）の財務データ比較。上の社名をクリックして会社を切り替えられます
Fidelity National Information Servicesの直近四半期売上が大きい（$2.8B vs $2.3B、バイオジェンの約1.2倍）。Fidelity National Information Servicesの純利益率が高く（18.2% vs -2.1%、差は20.3%）。Fidelity National Information Servicesの前年同期比売上増加率が高い（8.1% vs -7.1%）。Fidelity National Information Servicesの直近四半期フリーキャッシュフローが多い（$739.0M vs $468.0M）。過去8四半期でFidelity National Information Servicesの売上複合成長率が高い（6.8% vs -0.2%）
バイオジェンは米国マサチューセッツ州ケンブリッジに本拠を置く多国籍バイオテクノロジー企業で、神経疾患の治療分野を専門としています。主力製品には多発性硬化症治療薬のテクフィデラ、脊髄性筋萎縮症治療薬のスピンラザ、フリードライヒ運動失調症治療薬のスカイクラリスなどがあり、難病・神経疾患患者向けの革新的治療法の提供に注力しています。
Fidelity National Information Services（FIS）は米国発の多国籍企業で、金融テクノロジー分野を主力として多様な金融商品・サービスを提供しています。年間約750億件の取引を処理し、約9兆米ドルの資金移動を支援し、世界2万社以上の顧客にサービスを展開しています。
BIIB vs FIS — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $2.3B | $2.8B |
| 純利益 | $-48.9M | $511.0M |
| 粗利率 | 78.3% | 38.3% |
| 営業利益率 | -2.5% | 18.8% |
| 純利益率 | -2.1% | 18.2% |
| 売上前年比 | -7.1% | 8.1% |
| 純利益前年比 | -118.3% | 97.3% |
| EPS（希薄化後） | $-0.35 | $0.98 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $2.3B | $2.8B | ||
| Q3 25 | $2.5B | $2.7B | ||
| Q2 25 | $2.6B | $2.6B | ||
| Q1 25 | $2.4B | $2.5B | ||
| Q4 24 | $2.5B | $2.6B | ||
| Q3 24 | $2.5B | $2.6B | ||
| Q2 24 | $2.5B | $2.5B | ||
| Q1 24 | $2.3B | $2.5B |
| Q4 25 | $-48.9M | $511.0M | ||
| Q3 25 | $466.5M | $264.0M | ||
| Q2 25 | $634.8M | $-470.0M | ||
| Q1 25 | $240.5M | $77.0M | ||
| Q4 24 | $266.7M | $259.0M | ||
| Q3 24 | $388.5M | $224.0M | ||
| Q2 24 | $583.6M | $243.0M | ||
| Q1 24 | $393.4M | $724.0M |
| Q4 25 | 78.3% | 38.3% | ||
| Q3 25 | 73.4% | 37.8% | ||
| Q2 25 | 77.1% | 36.4% | ||
| Q1 25 | 74.1% | 34.7% | ||
| Q4 24 | 76.2% | 36.9% | ||
| Q3 24 | 74.1% | 38.0% | ||
| Q2 24 | 77.8% | 38.2% | ||
| Q1 24 | 76.3% | 37.1% |
| Q4 25 | -2.5% | 18.8% | ||
| Q3 25 | 22.0% | 16.8% | ||
| Q2 25 | 28.1% | 15.6% | ||
| Q1 25 | 12.8% | 13.7% | ||
| Q4 24 | 11.9% | 18.5% | ||
| Q3 24 | 18.3% | 19.1% | ||
| Q2 24 | 28.3% | 15.2% | ||
| Q1 24 | 20.3% | 14.6% |
| Q4 25 | -2.1% | 18.2% | ||
| Q3 25 | 18.4% | 9.7% | ||
| Q2 25 | 24.0% | -18.0% | ||
| Q1 25 | 9.9% | 3.0% | ||
| Q4 24 | 10.9% | 10.0% | ||
| Q3 24 | 15.8% | 8.7% | ||
| Q2 24 | 23.7% | 9.8% | ||
| Q1 24 | 17.2% | 29.3% |
| Q4 25 | $-0.35 | $0.98 | ||
| Q3 25 | $3.17 | $0.50 | ||
| Q2 25 | $4.33 | $-0.90 | ||
| Q1 25 | $1.64 | $0.15 | ||
| Q4 24 | $1.82 | $0.51 | ||
| Q3 24 | $2.66 | $0.41 | ||
| Q2 24 | $4.00 | $0.44 | ||
| Q1 24 | $2.70 | $1.25 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | — | $599.0M |
| 総負債低いほど良い | $6.3B | $9.1B |
| 株主資本純資産 | $18.3B | $13.9B |
| 総資産 | $29.4B | $33.5B |
| 負債/資本比率低いほどレバレッジが低い | 0.34× | 0.65× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | — | $599.0M | ||
| Q3 25 | — | $571.0M | ||
| Q2 25 | — | $581.0M | ||
| Q1 25 | — | $805.0M | ||
| Q4 24 | — | $834.0M | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $3.3B |
| Q4 25 | $6.3B | $9.1B | ||
| Q3 25 | $6.3B | $8.9B | ||
| Q2 25 | $6.3B | $8.9B | ||
| Q1 25 | $4.5B | $8.7B | ||
| Q4 24 | $6.3B | $9.7B | ||
| Q3 24 | $4.5B | $10.5B | ||
| Q2 24 | $6.3B | $10.6B | ||
| Q1 24 | $6.3B | $10.6B |
| Q4 25 | $18.3B | $13.9B | ||
| Q3 25 | $18.2B | $13.9B | ||
| Q2 25 | $17.6B | $14.2B | ||
| Q1 25 | $17.0B | $15.1B | ||
| Q4 24 | $16.7B | $15.7B | ||
| Q3 24 | $16.4B | $16.6B | ||
| Q2 24 | $15.9B | $17.0B | ||
| Q1 24 | $15.2B | $18.0B |
| Q4 25 | $29.4B | $33.5B | ||
| Q3 25 | $29.2B | $33.0B | ||
| Q2 25 | $28.3B | $33.4B | ||
| Q1 25 | $28.0B | $32.8B | ||
| Q4 24 | $28.0B | $33.8B | ||
| Q3 24 | $28.3B | $34.3B | ||
| Q2 24 | $26.8B | $34.6B | ||
| Q1 24 | $26.6B | $35.9B |
| Q4 25 | 0.34× | 0.65× | ||
| Q3 25 | 0.35× | 0.64× | ||
| Q2 25 | 0.36× | 0.63× | ||
| Q1 25 | 0.27× | 0.57× | ||
| Q4 24 | 0.38× | 0.62× | ||
| Q3 24 | 0.28× | 0.63× | ||
| Q2 24 | 0.40× | 0.62× | ||
| Q1 24 | 0.41× | 0.59× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $511.9M | $758.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $468.0M | $739.0M |
| FCFマージンFCF / 売上 | 20.5% | 26.3% |
| 設備投資強度設備投資 / 売上 | 1.9% | 0.7% |
| キャッシュ転換率営業CF / 純利益 | — | 1.48× |
| 直近12ヶ月FCF直近4四半期 | $2.1B | $2.5B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $511.9M | $758.0M | ||
| Q3 25 | $1.3B | $1.0B | ||
| Q2 25 | $160.9M | $382.0M | ||
| Q1 25 | $259.3M | $457.0M | ||
| Q4 24 | $760.9M | $782.0M | ||
| Q3 24 | $935.6M | $641.0M | ||
| Q2 24 | $625.8M | $546.0M | ||
| Q1 24 | $553.2M | $206.0M |
| Q4 25 | $468.0M | $739.0M | ||
| Q3 25 | $1.2B | $952.0M | ||
| Q2 25 | $134.3M | $343.0M | ||
| Q1 25 | $222.2M | $420.0M | ||
| Q4 24 | $721.6M | $764.0M | ||
| Q3 24 | $900.6M | $605.0M | ||
| Q2 24 | $592.3M | $530.0M | ||
| Q1 24 | $507.3M | $179.0M |
| Q4 25 | 20.5% | 26.3% | ||
| Q3 25 | 48.4% | 35.0% | ||
| Q2 25 | 5.1% | 13.1% | ||
| Q1 25 | 9.1% | 16.6% | ||
| Q4 24 | 29.4% | 29.4% | ||
| Q3 24 | 36.5% | 23.5% | ||
| Q2 24 | 24.0% | 21.3% | ||
| Q1 24 | 22.1% | 7.3% |
| Q4 25 | 1.9% | 0.7% | ||
| Q3 25 | 1.8% | 2.2% | ||
| Q2 25 | 1.0% | 1.5% | ||
| Q1 25 | 1.5% | 1.5% | ||
| Q4 24 | 1.6% | 0.7% | ||
| Q3 24 | 1.4% | 1.4% | ||
| Q2 24 | 1.4% | 0.6% | ||
| Q1 24 | 2.0% | 1.1% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | 2.73× | 3.83× | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 1.08× | 5.94× | ||
| Q4 24 | 2.85× | 3.02× | ||
| Q3 24 | 2.41× | 2.86× | ||
| Q2 24 | 1.07× | 2.25× | ||
| Q1 24 | 1.41× | 0.28× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
FIS
| Banking Solutions | $1.6B | 57% |
| Other | $701.0M | 25% |
| Capital Market Solutions | $508.0M | 18% |
